

provide rapid and flexible support to Zanzibar to accelerate evidence-based, person-centered HIV prevention and treatment program implementation at both facility and community levels, align HSS strengthening activities towards epidemic control, and ensure a comprehensive, coordinated, and strategic approach to the HIV response by organizing policies and interventions supported by reliable epidemiologic and program data. Funding amounts for years 2–5 will be set at continuation.

DATES: The period for this award will be September 30, 2023, through September 29, 2028.

FOR FURTHER INFORMATION CONTACT: Angela Schaad, Center for Global Health, Centers for Disease Control and Prevention, 2448 Albert Luthuli Rd, NIMR Complex | P.O. Box 9123 Dar es Salaam, Tanzania, Telephone: 255 677 680 051, Email: kin7@cdc.gov.

SUPPLEMENTARY INFORMATION: The single-source award will enhance collaboration between PEPFAR and the MOHZ to scale up HIV/TB services and improve quality of service delivery by reducing barriers to access.

The MOHZ is in a unique position to conduct this work in terms of its mandate and existing infrastructure to address the HIV strategy throughout Zanzibar.

Summary of the Award

Recipient: Ministry of Health Zanzibar (MOHZ).

Purpose of the Award: The purpose of this award is to provide rapid and flexible support to Zanzibar to accelerate evidence-based, person-centered HIV prevention and treatment program implementation at both facility and community levels, align HSS strengthening activities towards epidemic control, and ensure a comprehensive, coordinated, and strategic approach to the HIV response by organizing policies and interventions supported by reliable epidemiologic and program data.

Amount of Award: The approximate year 1 funding amount will be \$5,000,000 in Federal Fiscal Year (FFY) 2023 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation.

Authority: This program is authorized under Public Law 108–25 (the United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act of 2003).

Period of Performance: September 30, 2023 through September 29, 2028.

Dated: March 9, 2023.

Terrance Perry,

Chief Grants Management Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023–05252 Filed 3–14–23; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Biodefense Science Board Public Meeting

AGENCY: Administration for Strategic Preparedness and Response (ASPR), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The National Biodefense Science Board (NBSB or the Board), authorized under the Public Health Service (PHS) Act, as added by the Pandemic and All-Hazards Preparedness Act of 2006 and amended by the Pandemic and All-Hazards Preparedness Reauthorization Act, will hold a virtual, public meeting on May 4, 2023, at 2:00 p.m. ET. The NBSB, managed and operated by the ASPR, provides expert advice and guidance to the Secretary of HHS regarding current and future chemical, biological, radiological, and nuclear threats, and other disaster preparedness and response matters. A detailed agenda and Zoom registration instructions will be available on the ASPR/NBSB public meeting web page at least 10 days in advance of the meeting.

FOR FURTHER INFORMATION CONTACT: CAPT Christopher Perdue, NBSB Designated Federal Official, via email message to NBSB@hhs.gov or (202) 480–7226.

SUPPLEMENTARY INFORMATION:

Procedures for Public Participation: The link to pre-register for the public meeting will be posted on the meeting website. The online meeting will use a webinar format and include American Sign Language interpretation and live captioning.

Members of the public may provide written comments or submit questions to the NBSB at any time via email to NBSB@hhs.gov and are encouraged to provide comments related to the draft recommendations when those are posted. Additionally, the NBSB invites stakeholders to request up to seven minutes to address the Board in-person during the meeting. The Board wishes to hear from experts from relevant biomedical, biodefense, or health industries; faculty or researchers at academic institutions; health professionals, health system experts, or

those who work in health care consumer organizations; or experts in state, Tribal, territorial, or local government agencies. Requests to provide remarks to the NBSB during the public meeting must be sent to NBSB@hhs.gov by April 21, 2023. In that request, please provide the speaker's name, title, position, and organization, with a brief description of the topic they will address. Requests to speak to the Board will be approved in consultation with the Board Chairperson and based on time available during the meeting.

Dawn O'Connell,

Assistant Secretary for Preparedness and Response.

[FR Doc. 2023–05274 Filed 3–14–23; 8:45 am]

BILLING CODE 4150–37–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (240) 276–0361.

Project: Mandatory Guidelines for Federal Workplace Drug Testing Programs (OMB No. 0930–0158)—Extension

SAMHSA will request OMB approval for extension of the Federal Drug Testing Custody and Control Form (CCF) for federal agency and federally regulated drug testing programs which must comply with the HHS Mandatory Guidelines for Federal Workplace Drug Testing Programs using Urine (UrMG) dated January 23, 2017 (82 FR 7920) and using Oral Fluid (OFMG) dated October 25, 2019, and OMB approval for information provided by test facilities (laboratories and Instrumented Initial Test Facilities, IITFs) for the National Laboratory Certification Program (NLCP).

The CCF is used by all federal agencies and employers regulated by the Department of Transportation (DOT) and the Nuclear Regulatory Commission (NRC) to document the collection and chain of custody of urine specimens at the collection site, for HHS-certified test facilities to report results, and for